Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovaBay Pharmaceuticals, Inc. Common Stock (NY:NBY)

3.255 -0.965 (-22.87%)
Streaming Delayed Price Updated: 2:43 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovaBay Pharmaceuticals, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Nasdaq Jumps Over 200 Points, Crude Oil Rises Sharply
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 41 companies made new 52-week lows. 
Via Benzinga
NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
Recap: NovaBay Pharmaceuticals Q2 Earnings
  NovaBay Pharmaceuticals (AMEX:NBY) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
NovaBay Pharmaceuticals Reports Second Quarter 2022 Financial Results
From NovaBay® Pharmaceuticals, Inc.
Via Business Wire
Earnings Preview For NovaBay Pharmaceuticals
  NovaBay Pharmaceuticals (AMEX:NBY) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement. 
Via Benzinga
NovaBay Pharmaceuticals to Hold Second Quarter 2022 Conference Call on August 11
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. 
Via Benzinga
NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova® Lid and Lash Spray for Lash Extensions
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals’ DERMAdoctor Products Now Available at Target.com and Urbanoutfitters.com
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Record Avenova® Sales During Amazon’s Prime Day Event
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals’ DERMAdoctor Products to be Featured at Leading B2B Beauty Trade Show Cosmoprof North America
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals: Q1 Earnings Insights
NovaBay Pharmaceuticals (AMEX:NBY) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
NovaBay Pharmaceuticals Reports First Quarter 2022 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Earnings Outlook For NovaBay Pharmaceuticals
NovaBay Pharmaceuticals (AMEX:NBY) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
NovaBay Pharmaceuticals Expands Top-Selling DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-Aging Formulations
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold First Quarter 2022 Conference Call on May 12
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Rise and shine! We're gearing up for another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday. Clarus Therapeutics Holdings, Inc. (NASDAQ:... 
Via Benzinga
23 Stocks Moving in Tuesday's Pre-Market Session
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS... 
Via Benzinga
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to QVC® to Discuss DERMAdoctor’s Eczema Treatment
From NovaBay Pharmaceuticals, Inc
Via Business Wire
NovaBay Pharmaceuticals Introduces Hydrating Cleansing Oil to its DERMAdoctor Calm Cool + Corrected Product Line
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, NovaBay Pharmaceuticals (AMEX:NBY) posted sales of $2.64 million. Earnings were up 93.1%, but NovaBay Pharmaceuticals still reported an overall loss of... 
Via Benzinga
NovaBay Pharmaceuticals Reports 2021 Fourth Quarter and Full Year Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
NovaBay Pharmaceuticals Earnings Preview
NovaBay Pharmaceuticals (AMEX:NBY) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that NovaBay... 
Via Benzinga
Earnings Scheduled For March 29, 2022
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million. 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.